{rfName}
Ph

Indexed in

License and use

Altmetrics

Analysis of institutional authors

De Oteyza J.p.Author

Share

Publications
>
Article

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma

Publicated to:Clinical Cancer Research. 26 (14): 3546-3556 - 2020-07-15 26(14), DOI: 10.1158/1078-0432.ccr-19-3239

Authors: Gordon LI, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau I, Radford JA, Pérez de Oteyza J, Zinzani PL, Iyer S, Townsend W, Karmali R, Miao H, Proscurshim I, Wang S, Wu Y, Stumpo K, Shou Y, Carpio C, Bosch F

Affiliations

Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England - Author
Houston Methodist Canc Ctr, Houston, TX USA - Author
Millennium Pharmaceut Inc, Cambridge, MA USA - Author
NorthShore Univ Hosp, Evanston, IL USA - Author
Northwestern Univ, Feinberg Sch Med, 676 N St Clair St,Suite 850, Chicago, IL 60611 USA - Author
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 676 N St Clair St,Suite 850, Chicago, IL 60611 USA - Author
Osped Papa Giovanni XXIII, Bergamo, Italy - Author
Royal Marsden Hosp, Sutton, Surrey, England - Author
Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA - Author
Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA - Author
Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy - Author
Univ CEU San Pablo, Hosp Univ Madrid Sanchinarro, Madrid, Spain - Author
Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England - Author
Univ Hosp Vall dHebron, Barcelona, Spain - Author
Univ Manchester, Manchester, Lancs, England - Author
Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA - Author
See more

Abstract

Keywords

ActivationAdministration, oralAdultAgedAged, 80 and overAlanine aminotransferaseAlkaline phosphataseAmylaseAnemiaAntineoplastic activityArea under the curveArticleAspartate aminotransferaseAstheniaB cell lymphomaCancerCancer patientChronic lymphocytic-leukemiaCohort analysisConstipationContinuous infusionCoughingCreatine kinaseCriteriaDecreased appetiteDiarrheaDose-response relationship, drugDrug absorptionDrug administration scheduleDrug blood levelDrug dose escalationDrug efficacyDrug half lifeDrug safetyDrug tolerabilityDrugs, investigationalFatigueFebrile neutropeniaFemaleFeverFlt3 protein, humanFms-like tyrosine kinase 3FostamatinibHeadacheHumanHumansHypophosphatemiaIntention to treat analysisLactate dehydrogenaseLymphoma, follicularLymphoma, large b-cell, diffuseMajor clinical studyMaleMiddle agedMivavotinibMulticenter studyMultiple cycle treatmentNauseaNeutropeniaOpen studyPeriorbital edemaPhase 1 clinical trialPneumocystis pneumoniaPneumoniaProtein kinase inhibitorsPyrimidinesPyrrolidinonesSepsisSide effectSpleen tyrosine kinaseSyk inhibitionSyk kinaseSyk protein, humanTak-659TargetThrombocytopeniaTime to maximum plasma concentrationTreatment outcomeTriacylglycerol lipaseTrialVomitingYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Cancer Research due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position 18/242, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 6.02, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-02, the following number of citations:

  • WoS: 10
  • Scopus: 19
  • Europe PMC: 8

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 32.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 32 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 7.6.
  • The number of mentions on the social network X (formerly Twitter): 14 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: China; Italy; United Kingdom; United States of America.